![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 16, 2008 11:07:25 PM
Is it actually feasible to ink a deal where one compound can be given rights for one indication but rights for other areas of target indications for that same compound to be kept to Cortex.
I might assume a delay in finalizing a deal may come from the complexity of how many indications might one ampakine compound be viable for and for that, what %royality for all of those considerations would be appropriate.
Also, if low-impact compound x is ready for dealing but low-impacts 2x and 4x are around the corner and will have the same target indications but with likely better potency and maybe better results, then why would a company finalize a deal just for compound x when a competitor can finalize a deal for 2x or 4x and obtain the best in class or why would they finalize a deal for compound x and or 2x when that gives Cortex an ability to come out with compound 4x and end up with the best in class.
Maybe I am thinking this way because I am thinking that ampakines have a low-impact and a high-impact variability; but beyond those two categories how much variability is there. Not potency but variability. Is there variability with new low-impact compounds for the mech of action and pharmacodynamics to change.
Now maybe changing names from CX-xxx, xx1, to more independendly associated names for each compound would promote ease of splitting up different low impacts
What cortex probably needs is to find the best partner who would be able to increase the cortex royalities depending on the viability and progress of the low-impact compounds.
This would allow Cortex to partner the low-impacts and develop pet uses +high-impacts for sole Cortex use or until deemed fit to partner the high-impacts/other.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM